Private Equity Portfolio News: WuXi AppTec Prices A-Share IPO
Hong Kong and Shanghai, May 8, 2018 / BioCentury / – – Services and manufacturing company WuXi AppTec Co. Ltd. (Shanghai:603259) raised RMB2.3 billion ($354 million) through the sale of…
Hong Kong and Shanghai, May 8, 2018 / BioCentury / – – Services and manufacturing company WuXi AppTec Co. Ltd. (Shanghai:603259) raised RMB2.3 billion ($354 million) through the sale of…
ChinaBio Today Report / Apr 29, 2018 Innovent of Suzhou announced its series E financing of $150 million. Capital Group Private Markets (CGPM) is leading this investment with $90 million,…
Hua Medicine, a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes, announced the closing of a combined Series D & Series E financing of…
Hong Kong, Shenzhen and San Francisco, January 7, 2018 – Ally Bridge Group (“ABG”), a global healthcare-focused investment firm, has entered into a strategic partnership with LifeTech Scientific Corporation (SEHK:…
CAMBRIDGE, Mass. & AUSTIN, Texas–(BUSINESS WIRE)–Aug. 28, 2017– Synlogic, Inc. and Mirna Therapeutics, Inc. today announced that the proposed merger of the two companies has closed following the approval of…
WuXi Biologics, a Chinese contract R&D services provider to the global pharmaceutical industry that was taken private by a PE-backed consortium in late 2015, gained 38% on its Hong Kong…
Ally Bridge, the healthcare investment group that whisked Shanghai-based Wuxi Pharmatech from under the noses of established global private equity firms in 2015, is “reaching an inflection point”, according to…
Wuxi Biologics has ‘scarcity value’, worth 10% to 15% of group Future HK IPO of Shandong Luoxin is possible The listings of Wuxi Biologics in Hong Kong and the remainder of WuxiPharmatech‘s assets in China will benefit from their…
Aerpio Pharmaceuticals, Inc. (the “Company”), a biopharmaceuticalcompany focused on advancing first-in-class treatments for ocular diseases, today announced thesuccessful completion of its reverse merger transaction with Aerpio Therapeutics, Inc. (“Aerpio”) and…
China’s Ally Bridge Group hit the investment world’s radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first…